# Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC

> **NCT03780283** · PHASE2 · UNKNOWN · sponsor: **First Hospital of Shijiazhuang City** · enrollment: 30 (estimated)

## Conditions studied

- Carcinoma
- Lung Neoplasm
- Small Cell Lung Cancer

## Interventions

- **DRUG:** Anlotinib Hydrochloride

## Key facts

- **NCT ID:** NCT03780283
- **Lead sponsor:** First Hospital of Shijiazhuang City
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-01
- **Primary completion:** 2020-01-01
- **Final completion:** 2022-01-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2018-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03780283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03780283, "Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC". Retrieved via AI Analytics 2026-09-05 from https://api.ai-analytics.org/clinical/NCT03780283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*